Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: A randomized, double-blind, controlled study

Table 1 Baseline demographic and clinical characteristics (%, mean ± SD)

Characteristics	Esomeprazole enteric-coated capsules	Esomeprazole magnesium	Statistics	P value
	(n = 30)	(n = 27)
Gender, n (%)
Male	20 (66.7)	20 (74.1)
Female	10 (33.3)	7 (25.9)	χ2 = 0.3725	0.5416
Age (yr)	44.2 ± 11.9	43.6 ± 11.1	t = -0.1981	0.8437
Height (cm)	163.1 ± 7.2	164.7 ± 7.0	t = 0.8339	0.4079
Systolic BP (mmHg)	114.5 ± 10.5	111.6 ± 8.2	t = -1.1730	0.2459
Diastolic BP (mmHg)	73.4 ± 7.4	74.3 ± 9.2	t = 0.3901	0.6980
Heart rate (bpm)	73.8 ± 8.5	75.1 ± 11.3	t = 0.4713	0.6393
Duration of DU (mo)	58.3 ± 61.2	58.6 ± 53.7	t = 0.0178	0.9859
Total score of symptoms	5.5 ± 2.6	5.2 ± 1.6	t = -0.5580	0.5794
Ulcer diameter (mm)	7.7 ± 2.6	7.5 ± 2.4	t = -0.2764	0.7833
Ulcer number
1, n (%)	23 (76.7)	23 (85.2)
2, n (%)	7 (23.3)	4 (14.8)	χ2 = 0.6621	0.4158

SD: Standard deviation; BPM: Beats per minute; DU: Duodenal ulcer.

Table 2 Adverse events during 4-wk therapy

Adverse event	Esomeprazole enteric-coated capsules (n = 30)	Esomeprazole magnesium (n = 27)
Dizziness	2	2
Diarrhea	1	0
Constipation	0	1
Face puffiness	1	0
Other	1 (cough)	1 (palpitation)
Total	5	4